Telemetry Investments’s Biogen BIIB Stock Holding History

Telemetry Investments’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-30,000	Closed	-$9.39M	–	107
2016 Q3	$9.39M	Buy	30,000 +20,000	+200%	+$5.92M	5.89%	2
2016 Q2	$2.42M	Buy	+10,000	New	+$2.64M	1.3%	21

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Telemetry Investments's BIIB Position: Q4 2022 in Review

Telemetry Investments opened a new position in Biogen (BIIB) in Q4 2022: 817 shares worth $226K. The stake represents 0.36% of the portfolio and ranks #68 among its holdings.

1,032 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Telemetry Investments held 817 shares of Biogen worth $226K as of Q4 2022.
Biogen was a new Telemetry Investments position in Q4 2022.
Biogen made up 0.36% of Telemetry Investments's portfolio in Q4 2022, its #68 holding.
1,032 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.